Natera, Inc.
Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera advances molecular diagnostics with integrity and scientific rigor, and supports integration of information provided by our tests into health care decision making. Our tests are clinically validated in over 100 peer-reviewed publications with over 1.3 million patients studied. We participated in the largest prospective studies to date in molecular diagnostics in oncology (CIRCULATE), women’s health (SMART), and organ health (Trifecta). We meet or exceed applicable industry and regulatory standards for all of our tests to deliver high-quality results, and have processed over 5 million tests in our CAP/CLIA‑certified labs.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Our Technology
Pioneers in individualized genetic testing
Cell-free DNA (cfDNA) can be found in everyone’s blood. Not only do our own cells release it, so do fetal, tumor, and donor organ cells. Using a simple blood draw, our technology precisely detects each of these types of cfDNA providing the insight to proactively inform treatment.
With a track record of constant innovation over the last 15 years, our technology has performed more cfDNA tests than any other.
Our cell-free DNA technology platform
Our cutting-edge technology platform combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.
Targeted SNPs
We evaluate single nucleotide polymorphisms (SNPs) – the 1% of DNA that makes us different from one another. Focusing on SNPs allows us to zero in on the most actionable and clinically important cfDNA. The precision and accuracy of our technology is what enables our tests to distinguish between the DNA of a mother and a baby, or an organ transplant donor and a recipient.
Our cell-free DNA technology workflow
Our refined workflow extends the boundaries of what’s possible with cfDNA testing by integrating high-yield DNA extraction with proprietary library preparation and bioinformatics. We’ve set the industry standard by creating cfDNA tests with greater than 99% sensitivity down to a single DNA molecule in a tube of blood.
Panorama: More than 2 million cell-free DNA tests performed
Panorama is the only non-invasive prenatal test (NIPT) that uses cell-free DNA and unique SNP-based technology, making it the #1 NIPT test in the US.
Validated by >50 peer-reviewed publications and >250 technology patents
The analytic and clinical validity of our technology has been described in leading scientific journals, including Nature, Science, and JAMA. Natera is the leader in peer-reviewed published data across cfDNA applications.